CONFLICT OF INTEREST
The authors declare no conflict of interest.
REFERENCES
1. Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet. 2014;383(9930):1749-1761.
2. Zhao H, Wang Q, Luo C, Liu L, Xie W. Recompensation of decompensated hepatitis B cirrhosis: Current status and challenges. BioMed Res Int. 2020;2020:9609731.
3. Wang W, Xiao P, Xu H, Niu J, Gao Y. Growing burden of alcoholic liver disease in China: A review. World J Gastroenterol. 2019;25(12):1445-1456.
4. Rehm J, Shield KD. Global alcohol-attributable deaths from cancer, liver cirrhosis, and injury in 2010. Alcohol Res. 2013;35(2):174-183.
5. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406-460.
6. Nilsson E, Anderson H, Sargenti K, Lindgren S, Prytz H. Clinical course and mortality by etiology of liver cirrhosis in Sweden: A population based, long-term follow-up study of 1317 patients. Aliment Pharm Ther. 2019;49(11):1421-1430.
7. García-Martínez R, Simón-Talero M, Córdoba J. Prognostic assessment in patients with hepatic encephalopathy. Dis Markers. 2011;31(3):171-179.
8. Fichet J, Mercier E, Genée O, et al. Prognosis and 1-year mortality of intensive care unit patients with severe hepatic encephalopathy. J Crit Care. 2009;24(3):364-370.
9. Clària J, Stauber RE, Coenraad MJ, et al. Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure. Hepatol. 2016;64(4):1249-1264.
10. Li Z, Wu H, Wei Y, et al. Impact of surveillance in chronic hepatitis B patients on long-term outcomes after curative liver resection for hepatocellular carcinoma. J Gastrointest Surg. 2020;24(9):1987-1995.
11. Huang H, Chen H, Hsu Y. Comparing the prognosis of patient with alcohol and nonalcohol-associated cirrhosis with bacteremia. Alcohol Alcohol. 2020;55(5):512-517.
12. Zhong HJ, Xiao P, Lin D, Zhou HM, He XX. Cirrhosis in wilson disease is characterized by impaired hepatic synthesis, leukopenia and thrombocytopenia. Int J Med Sci. 2020;17(10):1345-1350.
13. Moreau R, Elkrief L, Bureau C, et al. Effects of long-term norfloxacin therapy in patients with advanced cirrhosis. Gastroenterology. 2018;155(6):1816-1827.e1819.
14. Chen H, Zhang Y, Guo T, et al. Genetic variant rs72613567 of HSD17B13 gene reduces alcohol-related liver disease risk in Chinese Han population. Liver Int. 2020;40(9):2194-2202.
15. Hong Y, Sinn D, Gwak G, et al. Characteristics and outcomes of chronic liver disease patients with acute deteriorated liver function by severity of underlying liver disease. World J Gastroenterol. 2016;22(14):3785-3792.
16. Wang Z, Wu YF, Yue ZD, et al. Comparative study of indocyanine green-R15, Child-Pugh score, and model for end-stage liver disease score for prediction of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. World J Gastroenterol. 2021;27(5):416-427.
17. Zhou C, Huang Y, Shu C, et al. Splenectomy before hepatectomy for patients with hepatocellular carcinoma and hypersplenism: A retrospective study. Medicine. 2021;100(4):e24326.
18. Valery P, McPhail S, Stuart K, et al. Changing prevalence of aetiological factors and comorbidities among Australians hospitalised for cirrhosis. Intern Med J. 2020.
19. Toshikuni N, Izumi A, Nishino K, et al. Comparison of outcomes between patients with alcoholic cirrhosis and those with hepatitis C virus-related cirrhosis. J Gastroenterol Hepatol. 2009;24(7):1276-1283.
20. Lv Y, Lau W, Li Y, et al. Hypersplenism: History and current status. Exp Ther Med. 2016;12(4):2377-2382.
21. Qamar AA, Grace ND, Groszmann RJ, et al. Incidence, prevalence, and clinical significance of abnormal hematologic indices in compensated cirrhosis. Clin Gastroenterol Hepatol. 2009;7(6):689-695.
22. Sugimoto S, Yamagishi Y, Ebinuma H, Kanai T. Spur cell anemia associated with alcoholic cirrhosis. Intern Med. 2013;52(24):2831.
23. Zimmer V, Bittenbring J, Fries P, Lammert F. Severe mixed-type iron overload in alcoholic cirrhosis related to advanced spur cell anemia. Ann Hepatol. 2014;13(3):396-398.
24. Vaz J, Eriksson B, Strömberg U, Buchebner D, Midlöv P. Incidence, aetiology and related comorbidities of cirrhosis: a Swedish population-based cohort study. BMC gastroenterology. 2020;20(1):84.
25. Lee Y, Kim C, Suk K, et al. Differences in cognitive function between patients with viral and alcoholic compensated liver cirrhosis. Metab Brain Dis. 2016;31(2):369-376.
26. Qureshi MO, Khokhar N, Shafqat F. Ammonia levels and the severity of hepatic encephalopathy. J Coll Physicians Surg Pak. 2014;24(3):160-163.
27. Axley P, Ahmed Z, Arora S, et al. NASH is the most rapidly growing etiology for acute-on-chronic liver failure-related hospitalization and disease burden in the United States: A population-based study. Liver Transpl. 2019;25(5):695-705.
28. Shalimar, Kedia S, Mahapatra SJ, et al. Severity and outcome of acute-on-chronic liver failure is dependent on the etiology of acute hepatic insults: Analysis of 368 patients. J Clin Gastroenterol. 2017;51(8):734-741.
TABLE 1 Patient characteristics